Evidence map›Paper›PMID 40438993›Full record

ReviewCA: a cancer journal for clinicians

Reirradiation: Standards, challenges, and patient-focused strategies across tumor types.

Arnaud Beddok, Jonas Willmann, Anna Embring, Ane L Appelt, Panagiotis Balermpas, Kevin Chua, J Isabelle Choi, Bernice Simone Elger, Dorota Gabrys, Peter Hoskin and 12 more

Abstract readReview
In one paragraph

Review in CA: a cancer journal for clinicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Reirradiation of recurrent brain tumors: a review by the ESTRO CNS Focus Group.Clinical and translational radiation oncology · 2027
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Multi-institutional virtual peer review for reirradiation: dedicated workflow and one-year results.Technical innovations & patient support in radiation oncology · 2025
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Arnaud BeddokDepartment of Radiation Oncology, Institut Godinot, Reims, France.ORCID 0000-0002-5512-4161
Jonas WillmannDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-2531-3551
Anna EmbringDepartment of Oncology, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-5147-3276
Ane L AppeltLeeds Institute of Medical Research, University of Leeds, Leeds, UK.ORCID 0000-0003-2792-9218
Panagiotis BalermpasDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-5261-6446
Kevin ChuaDivision of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0000-0002-1338-0781
J Isabelle ChoiDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Bernice Simone ElgerInstitute for Biomedical Ethics, University of Basel, Basel, Switzerland.ORCID 0000-0002-4249-7399
Dorota GabrysDepartment of Radiation Oncology, Maria Sklodowska-Curie National Research Institute of Oncology-Gliwice Branch, Glliwice, Poland.ORCID 0000-0001-9096-2788
Peter HoskinMount Vernon Cancer Center and University of Manchester, Manchester, UK.ORCID 0000-0001-8323-9567
Maximilian NiyaziDepartment of Radiation Oncology, University Hospital Tubingen, Tubingen, Germany.ORCID 0000-0002-7711-9486
David PasquierAcademic Department of Radiation Oncology, Oscar Lambret Center, Lille, France.ORCID 0000-0001-6019-7309
Kelly ParadisDepartment of Radiation Oncology, Michigan Medicine, Ann Arbor, Michigan, USA.ORCID 0000-0003-4950-3840
Orit Kaidar-PersonOncology Institute, Sheba Medical Center, Ramat Gan, Israel.ORCID 0000-0003-4023-1869
Corien PlaisierReintegration Coach, Breda, Netherlands.
Nicole C SchmittDepartment of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0002-0571-3531
Conor E SteuerDepartment of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA.ORCID 0000-0001-6528-6319
Juliette ThariatDepartment of Radiation Oncology, Baclesse Cancer Center, Caen, France.ORCID 0000-0003-4755-496X
Sue S YomDepartment of Radiation Oncology, University of California-San Francisco, San Francisco, California, USA.ORCID 0000-0002-0779-7476
Philip PoortmansDepartment of Radiation Oncology, Iridium Netwerk, Wilrijk-Antwerp, Belgium.ORCID 0000-0001-7400-2293
Eliana Vasquez OsorioDivision of Cancer Sciences, University of Manchester, Manchester, UK.ORCID 0000-0003-0741-994X
Nicolaus AndratschkeDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-3647-5916

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reirradiation (reRT), defined as administering a course of radiation therapy to a specific area previously irradiated, is an evolving treatment strategy for locoregionally recurrent cancer that offers significant potential and poses inherent challenges. Advances in such techniques as intensity-modulated and stereotactic body radiation therapy have improved precision, making reRT a viable option for complex scenarios previously deemed high-risk. Nevertheless, reRT remains associated with substantial risks-including life-threatening side effects, functional impairments, and psychosocial effects-which must be carefully balanced against the patient's overall health and the likelihood of achieving cancer control or palliation. Patient selection is essential to optimize outcomes while mitigating risks. Decisions should account for tumor characteristics at the time of primary diagnosis and recurrence, elapsed time since prior treatment, the possibility of delivering meaningful doses to the tumor, and the cumulative irradiation tolerance of normal tissues. Advanced imaging modalities, such as functional magnetic resonance imaging and fluorine-18-labeled fluorodeoxyglucose-positron emission tomography, are important for distinguishing recurrences from treatment-induced changes, refining treatment targets, and minimizing exposure to healthy tissue. Combined treatment with systemic regimens-targeted therapies and immunotherapy in particular-offers promising opportunities but requires coordination to manage side effects. Standardized guidelines, such as those from the European Society of Therapeutic Radiology and Oncology-European Society for Research and Treatment of Cancer, are essential for improving the consistency of reporting, guiding clinical decision making, and fostering patient-centered care. Multidisciplinary collaboration and ongoing research, particularly through clinical trials, are central to fully exploiting reRT strategies. In addition, the development of innovative techniques, such as proton therapy, would likely enable safer treatments. These efforts aim to improve the therapeutic balance of reRT, enhancing outcomes and quality of life.

Indexed as

Neoplasm Recurrence, LocalNeoplasmsProton TherapyRadiosurgeryRadiotherapy, Intensity-ModulatedRe-IrradiationClinical Decision-MakingHumansMagnetic Resonance ImagingPalliative CarePatient Care PlanningPatient-Centered CarePatient SelectionPositron-Emission TomographyPractice Guidelines as TopicQuality of Lifeadvanced imaging techniquesdecision‐makinglocoregional recurrenceradiation oncologyreirradiation

Identifiers

PMID40438993
PMCPMC12593330

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.